Oral Medicine and Radiology Kothiwal Dental College and Research Centre, Moradabad, India
Oral submucous fibrosis is a precancerous condition of the oral cavity and pharynx commonly encountered in South-Asian population. Hereby, the author presents a novel treatment for the same.
AIM: Efficacy and safety of intralesional xanthinol nicotinate in treatment of various stages of oral submucous fibrosis.
METHOD: This study included sixty patients clinically diagnosed with oral submucous fibrosis divided into two groups. Group I patients were subjected to intralesional xanthinol nicotinate injections biweekly for a period of four months while Group II patients were given intralesional saline injections biweekly for four months. All the patients were instructed to perform mouth opening physiotherapy regimen. At each visit, parameters like increase in inter-incisal distance, cheek flexibility, tongue protrusion and relief from burning sensation were measured and recorded.
RESULT: At the end of four months, in group I, an increase in mean values of inter-incisal distance, cheek flexibility, tongue protrusion and significant decrease in burning sensation was observed (p< 0.001).
CONCLUSION: Xanthinol nicotinate, a peripheral vasodilator, when injected intralesionally in oral submucous fibrosis patients not only provides relief from burning sensation but also results in increased mouth opening, tongue protrusion and cheek flexibility.
Keywords: Oral submucous fibrosis, xanthinol nicotinate, peripheral vasodilator, antioxidant.